An OHE report analyses the rise in NICE’s optimised decisions from 2025 to 2024 and how they affect patient access, HTA ...

Health Technology Assessment (HTA) agencies evaluate and make decisions on the use, funding, or reimbursement of health technologies based on clinical and economic evidence. Economic evaluations can ...

Immunisation programmes are foundational to public health. Organised by health authorities, they systematically deliver vaccines to susceptible populations to prevent the spread of infectious diseases ...

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Adam Raymakers and Chris Skedgel take us to Canada. Canada has a universal single-payer ...

Neil McAuslane PhD, MSc, BSc. Scientific Director of the Centre for Innovation in Regulatory Science (CIRS) overseeing the scientific content of both CIRS regulatory and HTA programmes. Key research ...

Chris is an expert in economic evaluation. His research focuses on significant methodological and policy challenges relating to the value of interventions and programmes for health. At OHE, Chris’s ...

Oriol has built a career in the planning, policy and decision-making environment, participating not just in the micro management, but also being deeply involved on the meso and macro policy areas.

Phill has over 25 years’ experience in the use of pharmaceutical industry data and information. His research interests include the economics of the pharmaceutical market, the productivity, and outputs ...

Professor John Cairns is a Professor of Health Economics at the London School of Hygiene and tropical Medicine.

Alastair Fischer Ph.D. has had a long career in statistics, economics and public health. He has a BSc from the University of Adelaide majoring in Pure Mathematica and Statistics, a BEc from the ...